Shuning Kong

GNAZ suppresses lung adenocarcinoma progression through HUWE1-mediated KIF11 ubiquitination and modulates the response to osimertinib

Osimertinib is a standard targeted therapy for EGFR-mutant lung adenocarcinoma (LUAD), yet substantial variation in treatment response remains a clinical problem. Here, we investigated the role of GNAZ, a heterotrimeric G-protein α-subunit that remains poorly characterized in lun...